Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 3/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.35 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2832503 | 0.88 | KCNH2 (0.49) | KCNH2MMP1ADAM17FFAR1MAOB | |
| SCHEMBL483562 | 0.88 | KCNH2 (0.48) | KCNH2MMP1ADAM17GPR119MAOB | |
| SCHEMBL10167529 | 0.88 | KCNH2 (0.38) | KCNH2ADAM17MAOBSCN3A | |
| SCHEMBL310836 | 0.88 | KCNH2 (0.48) | KCNH2MMP1ADAM17GPR119MAOB | |
| SCHEMBL483743 | 0.86 | KCNH2 (0.43) | KCNH2GPR119 | |
| SCHEMBL484165 | 0.83 | SCN3A (0.48) | KCNH2MMP1ADAM17GPR119MAOB | |
| SCHEMBL483702 | 0.83 | SCN3A (0.48) | KCNH2MMP1ADAM17GPR119MAOB | |
| SCHEMBL483783 | 0.83 | KCNH2 (0.51) | KCNH2MMP1ADAM17GPR119FFAR1 | |
| SCHEMBL483138 | 0.80 | DDB1 (0.36) | — | |
| SCHEMBL310424 | 0.80 | DDB1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153623-B2 | Compounds | Convergence Pharmaceuticals Limited (GB) | 2012-04-10 | — | — | US | disclosed |
| US-8153623-B2 | Compounds | Convergence Pharmaceuticals Limited (GB) | 2012-04-10 | — | — | US | disclosed |
| US-8153623-B2 | Compounds | Convergence Pharmaceuticals Limited (GB) | 2012-04-10 | — | — | US | disclosed |
| EP-1934176-B1 | QUATERNARY ALPHA-AMINOCARBOXAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS | GLAXO GROUP LTD (GB) | 2012-02-01 | — | — | EP | disclosed |
| US-20100324022-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-20100324022-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-7803833-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-7803833-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-20080293753-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-11-27 | — | — | US | disclosed |
| US-20080293753-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324022-A1 | NOVEL COMPOUNDS | CYP46A1, NPC1, CYP11B1 | KCNH2 3260/4885MMP1 3314/4885ADAM17 2157/4885 |
| US-20080293753-A1 | Novel Compounds | CACNA1E, CACNA1A, SCN1B | KCNH2 15/4885MMP1 4738/4885ADAM17 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.